Dena M. Minning

934 total citations · 1 hit paper
7 papers, 722 citations indexed

About

Dena M. Minning is a scholar working on Cell Biology, Infectious Diseases and Genetics. According to data from OpenAlex, Dena M. Minning has authored 7 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Cell Biology, 2 papers in Infectious Diseases and 2 papers in Genetics. Recurrent topics in Dena M. Minning's work include Hemoglobin structure and function (3 papers), Hemoglobinopathies and Related Disorders (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Dena M. Minning is often cited by papers focused on Hemoglobin structure and function (3 papers), Hemoglobinopathies and Related Disorders (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Dena M. Minning collaborates with scholars based in United States. Dena M. Minning's co-authors include William Sheridan, Y.S. Babu, Shanta Bantia, Pravin L. Kotian, Daniel E. Goldberg, Andrew J. Gow, Jonathan S. Stamler, Joseph Bonaventura, Rod D. Braun and Mark W. Dewhirst and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Dena M. Minning

7 papers receiving 701 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430

2014 461 citations Travis K. Warren, Jay Wells et al. Nature profile →

Peers

Countries citing papers authored by Dena M. Minning

Since Specialization

Citations

This map shows the geographic impact of Dena M. Minning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dena M. Minning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dena M. Minning more than expected).

Fields of papers citing papers by Dena M. Minning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dena M. Minning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dena M. Minning. The network helps show where Dena M. Minning may publish in the future.

Co-authorship network of co-authors of Dena M. Minning

This figure shows the co-authorship network connecting the top 25 collaborators of Dena M. Minning. A scholar is included among the top collaborators of Dena M. Minning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dena M. Minning. Dena M. Minning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Antibody-interferon-alpha fusion protein (IGN002) for the treatment of b-cell non-Hodgkin lymphomas: A phase 1, first-in-human, dose-escalation trial. 2016 ·Journal of Clinical Oncology ·Patricia A. Young, Nam H. Dang, Loretta J. Nastoupil, Dena M. Minning, Michael J. Gresser, John M. Timmerman	6
2	Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas 2015 ·Blood ·John M. Timmerman, (unknown), Reiko Yamada, Patricia A. Young, Dena M. Minning, Raj Sachdev, Michael J. Gresser, Sanjay D. Khare, Sherie L. Morrison	2
3	Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 breakdown → 2014 ·Nature ·Travis K. Warren, Jay Wells, Rekha G. Panchal, Kelly S. Stuthman, Nicole L. Garza, Sean A. Van Tongeren, Lián Dŏng, Cary Retterer, Brett Eaton, Gianluca Pegoraro, Shelley P. Honnold, Shanta Bantia, Pravin L. Kotian, Xilin Chen, (unknown), Lisa S. Welch, Dena M. Minning, Y.S. Babu, William Sheridan, Sina Bavari	461
4	BCX4430, a Novel Nucleoside Analog, Effectively Treats Yellow Fever in a Hamster Model 2014 ·Antimicrobial Agents and Chemotherapy ·Justin G. Julander, Shanta Bantia, (unknown), Dena M. Minning, Pravin L. Kotian, John D. Morrey, Donald F. Smee, William Sheridan, Y.S. Babu	70
5	Ascaris haemoglobin is a nitric oxide-activated ‘deoxygenase’ 1999 ·Nature ·Dena M. Minning, Andrew J. Gow, Joseph Bonaventura, Rod D. Braun, Mark W. Dewhirst, Daniel E. Goldberg, Jonathan S. Stamler	170
6	Determinants of Ascaris Hemoglobin Octamer Formation 1998 ·Journal of Biological Chemistry ·Dena M. Minning, Daniel E. Goldberg	7
7	Subunit Interactions in Ascaris Hemoglobin Octamer Formation 1995 ·Journal of Biological Chemistry ·Dena M. Minning, Andrew P. Kloek, Jian Yang, F. Scott Mathews, Daniel E. Goldberg	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact